RE:RE:RE:RE:RE:Where we stand
From what I'm understanding of the warrants and financing... they didn't want the warrants exercized. Financing is pretty much a done deal. FDA approval for glaucoma imaging shouldn't take long as it is considered an add-on. First quarter of this year will be included in the YE. I suspect it's being included because it is part of the continuim of growth they've experienced this past year. I believe the most revenue increase will show up in the second half of this year. From the sounds of it... we'll be getting several very positive NRs in the weeks to come. The impression I'm getting is that up coming news will instill confidence that Diagnos is the real deal. YE has to be out by next week and from what I understand, they held off deliberately to include insight into this year's Q1. I'm not hoping for stellar but rather... promising, confidence building news. As long as investors can see that Diagnos is making stellar progress and that we're on a short road to profitability... I think we'll get the rise we've all been waiting for. jmo